Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1992 1
1993 1
1996 2
1997 3
1998 3
1999 1
2000 1
2001 2
2002 3
2003 1
2004 3
2005 2
2006 3
2007 3
2008 3
2009 7
2010 4
2011 3
2012 5
2013 4
2014 5
2015 3
2016 5
2017 6
2018 3
2019 4
2020 5
2021 7
2022 8
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
In Response.
Nisman B, Oleinikov K, Nechushtan H, Maimon O, Atlan K, Peled N, Gross D, Peretz T, Meirovitz A, Grozinsky-Glasberg S. Nisman B, et al. Among authors: nechushtan h. J Thorac Oncol. 2023 Nov;18(11):e139-e141. doi: 10.1016/j.jtho.2023.08.032. J Thorac Oncol. 2023. PMID: 37879775 No abstract available.
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, Oxnard GR, Kherani J, Drilon A. Rotow J, et al. Among authors: nechushtan h. Clin Cancer Res. 2023 Aug 15;29(16):2979-2987. doi: 10.1158/1078-0432.CCR-22-2189. Clin Cancer Res. 2023. PMID: 36996322 Free PMC article.
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N, Roisman LC, Levison E, Dudnik J, Chernomordikov E, Heching N, Dudnik E, Keren-Rosenberg S, Nechushtan H, Salhab A, Hershkovitz D, Tsuriel S, Hannes V, Rotem O, Lazarev I, Lichtenberg R, Granot IS, Krayim B, Shalata W, Levin D, Krutman Y, Allen AM, Blumenfeld P, Lavrenkov K, Kian W. Peled N, et al. Among authors: nechushtan h. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):105-114. doi: 10.1016/j.ijrobp.2023.03.042. Epub 2023 Mar 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36925073 Clinical Trial.
A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy.
Golan S, Bar V, Salpeter SJ, Neev G, Creiderman G, Kedar D, Aharon S, Turovsky L, Zundelevich A, Shahar H, Shapira H, Mallel G, Stossel E, Gavert N, Straussman R, Dotan Z, Berger R, Stossel C, Golan T, Halperin S, Leibovici D, Breuer S, Rottenberg Y, Applebaum L, Hubert A, Nechushtan H, Peretz T, Zick A, Chertin B, Koulikov D, Sonnenblick A, Rosenbaum E. Golan S, et al. Among authors: nechushtan h. Front Med (Lausanne). 2023 Sep 28;10:1221484. doi: 10.3389/fmed.2023.1221484. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37840996 Free PMC article.
101 results